Israel Englander Adaptimmune Therapeutics PLC Transaction History

Millennium Management LLC

$199 Billion
Q3 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in Adaptimmune Therapeutics PLC stock. As of the latest transaction made, Millennium Management LLC holds 715,350 shares of ADAP stock, worth $515,052. This represents 0.0% of its overall portfolio holdings.

Number of Shares

715,350

Previous 779,615 8.24%

Holding current value

$515,052

Previous $764,000 11.13%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$0.92 - $1.39 $59,123 - $89,328	-64,265 Reduced 8.24%	715,350 $679,000
Q2 2024 Aug 14, 2024	SELL	$0.83 - $1.47 $37,818 - $66,979	-45,564 Reduced 5.52%	779,615 $764,000
Q1 2024 May 15, 2024	BUY	$0.7 - $1.75 $268,902 - $672,257	384,147 Added 87.1%	825,179 $1.3 Million
Q4 2023 Feb 14, 2024	SELL	$0.43 - $0.79 $90,699 - $166,634	-210,930 Reduced 32.35%	441,032 $348,000
Q2 2023 Aug 14, 2023	BUY	$0.9 - $1.51 $317,133 - $532,078	352,370 Added 117.62%	651,962 $599,000
Q1 2023 May 15, 2023	BUY	$1.06 - $2.16 $143,028 - $291,455	134,933 Added 81.95%	299,592 $327,000
Q4 2022 Feb 14, 2023	BUY	$1.05 - $2.53 $160,917 - $387,735	153,255 Added 1343.87%	164,659 $240,000
Q3 2022 Nov 14, 2022	SELL	$1.06 - $2.41 $117,361 - $266,830	-110,718 Reduced 90.66%	11,404 $12,000
Q2 2022 Aug 15, 2022	SELL	$1.33 - $2.28 $1.76 Million - $3.02 Million	-1,325,492 Reduced 91.56%	122,122 $208,000
Q1 2022 May 16, 2022	SELL	$1.73 - $4.06 $338,844 - $795,207	-195,864 Reduced 11.92%	1,447,614 $2.98 Million
Q4 2021 Feb 14, 2022	BUY	$3.5 - $5.68 $205,201 - $333,012	58,629 Added 3.7%	1,643,478 $6.16 Million
Q3 2021 Nov 15, 2021	BUY	$3.44 - $6.37 $2.25 Million - $4.17 Million	654,434 Added 70.34%	1,584,849 $8.19 Million
Q2 2021 Aug 16, 2021	SELL	$3.86 - $5.78 $2.65 Million - $3.97 Million	-686,118 Reduced 42.44%	930,415 $3.96 Million
Q1 2021 May 17, 2021	SELL	$4.9 - $6.83 $544,012 - $758,287	-111,023 Reduced 6.43%	1,616,533 $8.58 Million
Q4 2020 Feb 16, 2021	BUY	$4.0 - $9.2 $4.09 Million - $9.41 Million	1,022,800 Added 145.13%	1,727,556 $9.31 Million
Q3 2020 Nov 16, 2020	SELL	$7.66 - $10.78 $8.29 Million - $11.7 Million	-1,082,848 Reduced 60.58%	704,756 $5.62 Million
Q2 2020 Aug 14, 2020	BUY	$2.58 - $12.1 $855,850 - $4.01 Million	331,725 Added 22.79%	1,787,604 $17.9 Million
Q1 2020 May 14, 2020	BUY	$1.2 - $4.52 $1.16 Million - $4.35 Million	962,644 Added 195.17%	1,455,879 $3.96 Million
Q4 2019 Feb 14, 2020	SELL	$0.72 - $1.43 $303,250 - $602,288	-421,181 Reduced 46.06%	493,235 $592,000
Q3 2019 Nov 14, 2019	SELL	$1.43 - $3.81 $578,972 - $1.54 Million	-404,876 Reduced 30.69%	914,416 $1.38 Million
Q2 2019 Aug 15, 2019	BUY	$3.23 - $5.41 $1.45 Million - $2.44 Million	450,125 Added 51.79%	1,319,292 $5.3 Million
Q2 2019 Aug 14, 2019	SELL	$3.23 - $5.41 $5.55 Million - $9.3 Million	-1,719,573 Reduced 66.43%	869,167 $35.7 Million
Q1 2019 May 14, 2019	BUY	$3.63 - $6.06 $1.78 Million - $2.97 Million	490,468 Added 23.37%	2,588,740 $11.1 Million
Q4 2018 Feb 14, 2019	SELL	$3.76 - $14.16 $279,653 - $1.05 Million	-74,376 Reduced 3.42%	2,098,272 $12.1 Million
Q3 2018 Nov 14, 2018	BUY	$8.27 - $13.56 $10.9 Million - $18 Million	1,323,793 Added 155.95%	2,172,648 $29.5 Million
Q2 2018 Aug 14, 2018	SELL	$10.42 - $13.74 $6.55 Million - $8.64 Million	-628,786 Reduced 42.55%	848,855 $10.1 Million
Q1 2018 May 15, 2018	BUY	$7.1 - $11.56 $4.77 Million - $7.77 Million	672,046 Added 83.42%	1,477,641 $16.6 Million
Q4 2017 Feb 14, 2018	BUY	$6.68 - $8.74 $1.44 Million - $1.88 Million	215,439 Added 36.51%	805,595 $5.38 Million
Q3 2017 Nov 14, 2017	BUY	$4.93 - $8.93 $2.91 Million - $5.27 Million	590,156	590,156 $4.83 Million

Others Institutions Holding ADAP

# of Institutions

Shares Held

150M

Call Options Held

60.8K

Put Options Held

5.8K

View Full List

About Adaptimmune Therapeutics PLC

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $118M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

More about ADAP

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account